Picture this: You're battling the excruciating pain of gout, a form of arthritis that swells your joints and makes every step agony, and your doctor prescribes allopurinol – a go-to drug for millions in the U.S. But what if that very medication could trigger a life-threatening reaction? It's a scary reality, but exciting new research is shedding light on how to spot those at risk. Dive in, and you'll discover a groundbreaking genetic breakthrough that could save lives. And this is the part most people miss – it's not just about one gene; it's a whole new layer of protection tailored to diverse populations.
Gout, affecting around 6.1 million men and 2.2 million women in the United States, is an inflammatory arthritis caused by high levels of uric acid crystals building up in the joints. Allopurinol is a widely used treatment to lower those levels and ease the pain. However, for some, it can lead to severe cutaneous adverse reactions, or SCARs – serious skin conditions that, while rare, can be deadly. These reactions are often linked to specific genetic markers, and now, scientists have uncovered a new one that could revolutionize risk prediction.
For years, doctors have relied on a gene called HLA-B*58:01 to screen patients, especially in Southeast Asia, where it catches almost all cases of these dangerous reactions. But in the U.S., it's a different story. This marker misses over a third of at-risk patients overall, and up to 45% of Black individuals who might suffer severe side effects if given allopurinol. It's a gap that's left many vulnerable, and here's where it gets controversial – why has screening been pushed so hard based on assumptions that don't fully hold up across all groups?
Enter researchers from Vanderbilt University Medical Center, who've identified a second gene, HLA-A34:02. When combined with the original HLA-B58:01, this duo could predict risk in more than 80% of U.S. patients, according to a recent study in JAMA Dermatology. Think of it like adding a second lock to a door – together, they provide much stronger protection against unexpected dangers.
As lead author Elizabeth Phillips, MD, the John A. Oates Professor of Clinical Research and a professor in Medicine, Dermatology, Pharmacology, and Pathology, Microbiology, and Immunology at Vanderbilt, explains: 'We found a new genetic association, HLA-A34:02, which appears very important as a risk factor in U.S. allopurinol severe cutaneous adverse reactions patients.' She adds, 'The combination of HLA-A34:02 and HLA-B*58:01 would help explain risk in over 80% of patients.'
To understand SCARs better, let's break it down for beginners. These aren't just mild rashes; they're severe conditions like Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), which can cause skin to blister and peel off, or drug reaction with eosinophilia and systemic symptoms (DRESS), involving fever, organ swelling, and blood abnormalities. For allopurinol, SJS/TEN has a mortality rate of 20-30%, while DRESS clocks in at about 9%. Mortality is even higher for those with kidney or heart issues, who are more likely to need this drug.
But here's the intriguing twist: risk isn't universal. It's tied to genetics that vary by population. For example, the rate of carrying HLA-B*58:01 is about five times higher in Black Americans than in white Americans. That's why the American College of Rheumatology suggested in 2020 that Asian and Black patients get screened before starting allopurinol. Yet, the new study shows this isn't enough – it leaves significant gaps, especially in Black patients, where the gene was absent in nearly half the cases. This challenges the idea that one gene rules them all, and it raises questions about whether current guidelines are fair or sufficient for our diverse society.
Phillips points out, 'We are more comprehensively identifying that risk for drug reactions can be population specific based on genes prevalent in specific populations.' She elaborates, 'Risk in any given population is based on how commonly a drug is prescribed and then the carriage rate of specific genes associated with risk for that drug reaction in that specific population. We are learning that, in populations like the United States that are highly admixed for race and ethnicity, studies need to be conducted to identify the specific risk genes that are relevant.'
The research analyzed 16 patients at Vanderbilt with confirmed allopurinol-induced SCARs. While HLA-B*58:01 showed up in many, it was missing in a notable group, particularly among Black individuals. This underscores the need for broader testing. Ultimately, Phillips envisions 'developing drug hypersensitivity panels that could more comprehensively identify patients at risk for severe reactions to drugs regardless of their population of origin.'
If you're intrigued by genetics and health, you might also enjoy these related stories: A new method for creating reliable growth charts for kids with rare genetic disorders, a discovery of a previously unknown genetic cause for microcephaly, and how molecular evidence links better childhood brain function to a longer life.
This breakthrough not only highlights the power of personalized medicine but also sparks debate. Should genetic testing become standard before prescribing common drugs, even if it adds cost and complexity? Or is it overkill for rare risks? And what about ethical concerns – like ensuring tests are accessible to all, regardless of background? Do you think this could change how doctors approach treatments for conditions like gout? Is the focus on population-specific genes a step toward better care or a new form of exclusion? Share your opinions in the comments – I'd love to hear what you think!
Source: Journal reference: Campbell, C. N., et al. (2025). HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US. JAMA Dermatology. doi.org/10.1001/jamadermatol.2025.4240
Suggested Reading
Terms
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
Read the full Terms & Conditions (https://www.news-medical.net/medical/terms).
